Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9980531 | 1.00 | AAK1 (0.36) | AAK1PAX8 | |
| SCHEMBL10182576 | 0.89 | AAK1 (0.37) | AAK1PAX8 | |
| SCHEMBL27870991 | 0.88 | AAK1 (0.40) | AAK1PAX8 | |
| SCHEMBL27870993 | 0.88 | AAK1 (0.40) | AAK1PAX8 | |
| SCHEMBL21334068 | 0.84 | AAK1 (0.31) | AAK1PAX8 | |
| SCHEMBL1294210 | 0.84 | AAK1 (0.38) | AAK1PAX8 | |
| SCHEMBL27887125 | 0.81 | AAK1 (0.36) | AAK1PAX8 | |
| SCHEMBL19690733 | 0.79 | AAK1 (0.35) | AAK1 | |
| SCHEMBL21334151 | 0.79 | AAK1 (0.30) | AAK1 | |
| SCHEMBL1293882 | 0.79 | AAK1 (0.36) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| EP-2575475-A1 | INHIBITORS OF HCV NS5A | Presidio Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150243-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2373167-A1 | INHIBITORS OF HCV NS5A | Presidio Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065668-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | AAK1 1920/4885PAX8 4613/4885 |
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | AAK1 1920/4885PAX8 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.